pharmaceuticals

investor research

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

There are two events in the biotech world that can quickly bring down the price of a stock. One is to have a failed or, sometimes worse, a misunderstood clinical ...
Read Full Story »
buy sell

Can MEI Pharma Survive?

Biotech and pharmaceutical companies live and die by the sword of innovation, or specifically, by clinical trials that test new drug candidates. A successful trial can mean a boom in ...
Read Full Story »
Biotechnology word cloud

The Top 5 Biotech Stocks of 2015 — Average Gains So Far Over 200%

The multiyear run in major biotech stocks has not let up in 2015. Most of the large and mid-cap stocks in the industry are higher, but the smaller and lesser ...
Read Full Story »
generic drugs

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

It is a nice change sometimes when the prognosticators on Wall Street, who tend to follow each other's lead, are not only right, but investors come out on top. Almost ...
Read Full Story »
generic drugs

As Valeant Ups Salix Buyout, Will Endo Come Back?

Monday morning, Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Valeant Pharmaceuticals International Inc. (NYSE: VRX) both announced that they had entered into an agreement on their plan to merge based on ...
Read Full Story »
DNA

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases. A ...
Read Full Story »
179378515

5 Highly Unusual Stock Moves of the Past Week

The bull market may have seen an interruption this past week, but stocks are still very close to all-time highs and this bull market is now six years old. It ...
Read Full Story »
generic drugs

Par Pharma Files for IPO

Par Pharmaceutical Holdings Inc. filed its Form S-1 Friday with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the number ...
Read Full Story »
payoff

Salix Now Has 2 Merger Dance Partners

The merger situation around Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) just became much more complicated. Endo International PLC (NASDAQ: ENDP) has made a bid for Salix in a private letter sent to ...
Read Full Story »
biotech

The Gamble That Did Not Pay Off

Zogenix Inc. (NASDAQ: ZGNX) announced an agreement for the sale of its Zohydro ER (hydrocodone bitartrate) business to Pernix for $100 million. This transaction will be composed of $30 million ...
Read Full Story »
Pills

4 Top Pharmaceutical Stocks to Buy for Market Safety

Tuesday's big downward move reminded everybody that while things look encouraging for the stock market long term, momentum stocks tend to get absolutely eviscerated when a big volatility jump helps ...
Read Full Story »
fda_logo

Can AcelRx Overcome Yet Another FDA Roadblock?

AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) announced an update on the timing and potential content of its resubmission of the New Drug Application (NDA) for Zalviso. Unfortunately the update was not ...
Read Full Story »
462542665

Just How Expensive Is the Pharmacyclics Buyout?

Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official ...
Read Full Story »
biotech

Are Mylan Earnings Enough?

Monday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically the company had $1.05 in earnings per share (EPS) and ...
Read Full Story »
pills

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

After the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is ...
Read Full Story »